Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 2.73 billion CNY, with a net profit of 248 million CNY, and a non-recurring net profit of 205 million CNY, reflecting a year-on-year revenue decline of 14.63% but a net profit increase of nearly 2% [3] - The API business generated revenue of 1.883 billion CNY with a gross profit of 255 million CNY and a gross margin of 13.52% [3] - The CDMO business reported revenue of 549 million CNY, gross profit of 222 million CNY, and a gross margin of 40.43% [3] - The pharmaceutical business earned revenue of 298 million CNY, gross profit of 179 million CNY, and a gross margin of 60.09% [3] Group 2: Business Segment Performance - The API segment faced significant pressure with a revenue decline of 20% and a gross profit drop of 35%, leading to a gross margin decrease of 3.1 percentage points [3] - The CDMO segment showed strong performance with a 10% increase in sales and nearly 20% growth in gross profit, with a gross margin increase of 3.31 percentage points [3] - The pharmaceutical segment experienced a revenue decline of 12.8% and a gross profit decrease of 6.54%, but the gross margin improved by 4 percentage points [3] Group 3: Market Trends and Projections - The company anticipates a shift in business trends between 2024 and 2025, expecting a lower performance in the first half of 2025 compared to the previous year [4] - The CDMO business is projected to grow by 20% to 30% in 2025, with a normal gross margin range of 40% to 45% [6] - The company is actively expanding into new markets, including Southeast Asia and Africa, to mitigate domestic market pressures [7] Group 4: Share Buyback and Capital Management - The company has executed three share buyback plans, with the first in 2022 repurchasing 9.2 million shares for 200 million CNY, fully canceled [5] - The second buyback in 2024 involved 10.88 million shares for 153 million CNY, which was also approved for cancellation [5] - The third buyback plan is currently in process, with future stock incentive plans contingent on its completion [5] Group 5: R&D and Innovation - The company has enhanced its R&D capabilities significantly, particularly in the CDMO sector, by hiring experts from top international firms [6] - AI is being utilized to optimize fermentation processes, resulting in a nearly 70% increase in fermentation efficiency for certain products [13] - The company is developing new products and improving existing ones, with expectations of over 15 new product approvals by 2026 [8]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][29] Core Views - The company's revenue has shown a quarter-on-quarter increase, with rapid growth in new molecular business. The overall revenue for 2024 is 39.241 billion yuan, a decrease of 2.7%, but a 5.2% increase when excluding COVID-19 commercialization projects. The net profit attributable to the parent company is 9.450 billion yuan, down 1.6%, while the adjusted Non-IFRS net profit is 10.58 billion yuan, down 2.5% [6][3][5] - The CRDMO business model is driving growth, with revenue from chemical, testing, and biological services at 29.052 billion yuan (-0.4%, with an 11.2% increase excluding COVID-19 projects), 5.671 billion yuan (-13.3%), and 2.544 billion yuan (-0.3%) respectively [16][5] Summary by Sections Financial Performance - In Q4 2024, the company achieved a single-quarter revenue of 11.539 billion yuan (+6.9%) and a net profit of 2.917 billion yuan (+90.6%). The adjusted Non-IFRS net profit for the same quarter was 3.240 billion yuan (+20.4%) [6][3][5] - The gross profit margin for 2024 is 41.48% (+0.3pp), and the net profit margin is 24.38% (+0.3pp) [11][5] Business Segments - The small molecule CRO/CDMO business has shown strong growth, with over 460,000 new compounds synthesized and delivered in 2024 (+10%). The small molecule D&M business generated revenue of 17.87 billion yuan, with a 6.4% increase when excluding specific commercialization projects [23][5] - The TIDES business has also experienced rapid growth, achieving revenue of 5.80 billion yuan (+70.1%) and a 103.9% increase in orders on hand by the end of 2024 [23][5] Future Outlook - The company maintains a solid industry position, with steady quarterly performance improvements expected. The profit forecasts for 2025-2027 are adjusted upwards, with net profits projected at 11.162 billion yuan, 12.732 billion yuan, and 14.506 billion yuan respectively, reflecting year-on-year growth rates of 18.11%, 14.07%, and 13.93% [3][5][4]

证券研究报告 | 2025年04月20日 普洛药业（000739.SZ）--2025 年一季报点评 优于大市 原料药业务承压，CDMO 业务彰显韧性 核心观点 公司研究·财报点评 医药生物·化学制药 | 证券分析师：彭思宇 | 证券分析师：陈曦炳 | | --- | --- | | 0755-81982723 | 0755-81982939 | | pengsiyu@guosen.com.cn | chenxibing@guosen.com.cn | | S0980521060003 | S0980521120001 | 0755-81982723 0755-81982939 pengsiyu@guosen.com.cn chenxibing@guosen.com.cn 联系人：凌珑 021-60375401 linglong@guosen.com.cn 基础数据 | 投资评级 | | 优于大市(维持) | | --- | --- | --- | | 合理估值 | | | | 收盘价 | | 13.57 元 | | 总市值/流通市值 | | 15868/15862 百万元 | | 52 | 周最高价/最低价 ...

Market Performance - On April 17, 2025, the pharmaceutical sector had a change of +0.04%, outperforming the CSI 300 index by 0.06 percentage points, ranking 16th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (+0.98%), pharmaceutical distribution (+0.40%), and offline pharmacies (+0.35%) performed well, while other bioproducts (-0.57%), vaccines (-0.48%), and blood products (-0.22%) lagged [1] - Top three gainers in individual stocks were Kangpeng Technology (+20.00%), Nuosige (+10.06%), and Yisheng Pharmaceutical (+10.03%); top three losers were Changyao Holdings (-6.33%), Hasanlian (-5.26%), and Shouyao Holdings (-4.81%) [1] Industry News - On April 17, 2025, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved statistically significant positive results in a key Phase III clinical trial (ACHIEVE-1) [2] - The study evaluated the safety and efficacy of Orforglipron compared to a placebo in adults with type 2 diabetes who had poor blood sugar control through diet and exercise alone [2] - Orforglipron is a research-based, once-daily oral small molecule (non-peptide) GLP-1 receptor agonist that can be taken at any time of the day without food and drink restrictions [2] Company News - Huayuan Bio (300401) reported Q1 2025 revenue of 326 million yuan, a year-on-year decrease of 1.18%, with net profit attributable to the parent company at 97 million yuan, a year-on-year increase of 5.50%, and a non-recurring net profit of 88 million yuan, up 44.42% year-on-year [3] - Puluo Pharmaceutical (000739) reported Q1 2025 revenue of 2.73 billion yuan, a year-on-year decrease of 14.63%, with net profit attributable to the parent company at 249 million yuan, a year-on-year increase of 1.98%, and a non-recurring net profit of 206 million yuan, down 14.05% year-on-year [3] - Sanbo Brain Science (301293) reported 2024 revenue of 1.43 billion yuan, a year-on-year increase of 8.84%, with net profit attributable to the parent company at 105 million yuan, a year-on-year increase of 34.24%, and a non-recurring net profit of 94 million yuan, up 0.77% year-on-year [3] - Betta Pharmaceuticals (300558) reported 2024 revenue of 2.89 billion yuan, a year-on-year increase of 17.74%, with net profit attributable to the parent company at 403 million yuan, a year-on-year increase of 15.67%, and a non-recurring net profit of 410 million yuan, up 55.92% year-on-year [3]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][39]. Core Views - The company achieved a steady revenue growth of 4.77% in 2024, with total revenue reaching 12.022 billion yuan, while net profit slightly declined by 2.29% to 1.031 billion yuan [9][39]. - The report highlights that excluding the impact of large CDMO projects, all three major business segments showed comprehensive growth [2][39]. - The company is focusing on deepening its international strategy and optimizing quality management to ensure stable supply in its raw materials and CDMO business [3][39]. Summary by Sections Financial Performance - In 2024, the company reported a total revenue of 12.022 billion yuan, a growth of 4.77%, and a net profit of 1.031 billion yuan, down 2.29% year-on-year [9][39]. - The overall gross margin for 2024 was 23.85%, a decrease of 1.81 percentage points, while the net margin was 8.57%, down 0.63 percentage points [18][39]. Business Segments - The revenue from the raw material drug intermediates, CDMO, and formulation segments were 8.651 billion yuan (+8.32%), 1.884 billion yuan (-6.05%), and 1.256 billion yuan (+0.51%), respectively [2][39]. - The gross profit margins for these segments were 14.97% (-2.59pp), 41.06% (-1.23pp), and 60.81% (+7.67pp) [2][39]. Research and Development - The company increased its R&D expenses to 641 million yuan in 2024, a rise of 2.66% year-on-year, supporting the rapid growth of project numbers [3][39]. - The company has a rich pipeline with 1,601 CDMO quotation projects (+77% YoY) and 996 ongoing projects (+35% YoY) [31][39]. Market Strategy - The company is advancing its international strategy by establishing BD offices in key global markets such as Boston, Frankfurt, Tokyo, and Mumbai [3][39]. - The company aims to enhance its global supply chain and has successfully passed 265 audits in 2024 [3][39]. Profit Forecast - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 1.123 billion yuan, 1.257 billion yuan, and 1.399 billion yuan, reflecting growth rates of 8.9%, 11.9%, and 11.4%, respectively [4][39].

证券研究报告 | 2025年04月18日 普洛药业（000739.SZ）--2024 年年报点评 优于大市 全年营收增长 4.77%，利润端略有承压 全年营收稳步增长、利润端略有下滑。2024 全年公司实现营收 120.22 亿 元（+4.77%），归母净利润 10.31 亿元（-2.29%），扣非归母净利润 9.84 亿元（-4.09%）。其中，四季度单季营收 27.31 亿元（-8.15%），归母 净利润 1.61 亿元（-20.85%），扣非归母净利润 1.53 亿元（-22.81%）。 2024 年全年公司整体毛利率 23.85%，同比下降 1.81pp；净利率 8.57%， 同比下降 0.63pp。 剔除 CDMO 大项目影响，三大业务全面增长。2024 年公司原料药中间体、 CDMO 、 制 剂 板 块 营 收 分 别 为 86.51/18.84/12.56 亿 元 （+8.32%/-6.05%/+0.51%），剔除 2023 年同期 CDMO 业务新冠项目基数 影 响 ， 三 大 业 务 全 面 增 长 ， 毛 利 为 12.95/7.73/7.64 亿 元 （ -7.68%/-8.78%/+1 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,730,189,121.97, a decrease of 14.63% compared to ¥3,198,046,619.86 in the same period last year[5] - Net profit attributable to shareholders was ¥248,547,145.11, representing a slight increase of 1.98% from ¥243,716,289.99 year-on-year[5] - The basic and diluted earnings per share were both ¥0.2126, reflecting a growth of 2.02% from ¥0.2084 in the same period last year[5] - Net profit increased to ¥248,576,261.58 compared to ¥243,714,001.08, showing a growth of approximately 2.3%[18] - The total profit margin for the period was approximately 10.9%, slightly down from the previous margin of 11.1%[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥14,993,469.16, a decline of 105.35% compared to ¥280,125,473.87 in the previous year[5] - Operating cash flow generated a net outflow of ¥14,993,469.16, contrasting with a net inflow of ¥280,125,473.87 in the previous period[19] - Cash and cash equivalents decreased to CNY 3,465,233,609.71 from CNY 3,661,618,802.74, reflecting a decline of approximately 5.36%[14] - Cash and cash equivalents at the end of the period stood at ¥2,594,930,339.41, slightly down from ¥2,599,072,264.47[20] - Investment activities resulted in a net cash outflow of ¥91,370,688.15, compared to a larger outflow of ¥188,142,141.05 in the prior period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,708,540,956.72, a slight decrease of 0.16% from ¥12,729,008,610.16 at the end of the previous year[5] - Current assets totaled CNY 8,228,646,015.77, compared to CNY 8,186,761,774.66 at the start of the period, indicating a growth in liquidity[14] - Total liabilities decreased to CNY 5,709,989,761.76 from CNY 5,979,125,430.44, indicating a reduction of about 4.49%[15] - The company's equity attributable to shareholders increased to CNY 6,990,603,683.93 from CNY 6,741,964,785.16, reflecting an increase of approximately 3.69%[16] - Short-term borrowings decreased to CNY 668,156,422.52 from CNY 814,026,241.34, a reduction of about 17.94%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,719, with the largest shareholder holding 28.30% of the shares[10] - The company repurchased 10,880,000 shares, representing 0.93% of the total share capital[11] Investment and Other Income - The company reported a significant increase in investment income to ¥39,456,689.06, compared to a loss of -¥2,018,356.21 in the previous year[9] - Non-recurring gains and losses totaled ¥42,881,422.13, primarily from the disposal of non-current assets and government subsidies[6] Research and Development - Research and development expenses increased to ¥169,688,023.08 from ¥152,938,500.76, reflecting a rise of about 11%[17] Other Financial Metrics - The company's return on equity (ROE) was 4.00%, an increase of 0.16% compared to 3.84% from the previous year[5] - Accounts receivable financing increased by 195.96% to ¥539,323,041.79, mainly due to an increase in received bills[9] - Accounts receivable increased to CNY 1,832,342,320.15 from CNY 1,764,198,282.30, representing a growth of about 3.86%[14] - Inventory decreased to CNY 1,651,614,838.63 from CNY 1,860,088,103.67, showing a decline of approximately 11.21%[14] - The company reported a significant increase in long-term receivables, rising to CNY 3,888,628.75 from CNY 3,483,230.30, an increase of approximately 11.63%[15] - The company experienced a foreign exchange impact of ¥3,246,242.93 on cash and cash equivalents[20]

Group 1 - The core point of the article is that Prologis Pharmaceutical (000739) reported a decline in revenue for the first quarter of 2025, while net profit showed a slight increase [1] - The company's operating revenue for Q1 2025 was 2.73 billion yuan, representing a year-on-year decrease of 14.63% [1] - The net profit for the same period was 249 million yuan, which reflects a year-on-year growth of 1.98% [1]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]